BioNeutral Group has signed a collaborative agreement to expand its relationship with the Chertoff Group. Under the agreement, Chertoff Group principal Jeffrey Runge, and deputy chief operating officer Bennet Waters will devote their time exclusively to advising BioNeutral.
Moreover, Dr Runge will serve as senior medical advisor, and Dr Waters will serve as senior operations advisor.
In addition to Doctors Runge and Waters, other Chertoff Group principals will provide periodic support to BioNeutral regarding product testing and evaluation, acquisitions and procurement activities across commercial and federal targets, and capital-raising strategies.
Stephen Browand, president and CEO of BioNeutral Group, said: “It’s exciting working with the Chertoff Group. We believe their collective talent, combined with BioNeutral’s world class chemistry, will make a significant difference in saving lives presently lost to infection. We are proud to combine our efforts to help combat communicable diseases and make the hospital and all health care facilities a safer place.”